Recombinant Human Growth Hormone (Genotropin(superscript ®)) in Treatment of Children with Growth Hormone Deficiency: The First Year Observation

基因工程生長激素治療生長激素缺乏兒童：第一年觀察

郭懷楓 (Hwai-Fong Kuo) ； 劉屏鍾(Ping-Chung Liu) ； 石光中(Kwan-Chung Shih) ； 李天行(Tian-Shing Lee) ； 何橈通(Low-Tone Ho)

《Acta Paediatrica Sinica》 33卷1期 (1992/02) Pp. 12-19

摘要

五位生長激素缺乏的兒童經診斷確定後，開始接受爲期一年的生長激素治療，劑量爲每天每公斤體重0.1國際單位皮下注射。所有小朋友在身高生長速度，骨骼生長速度等指標均有明顯的進步，結果分別爲：身高生長速度增加7.86±2.00公分/年，骨齡平均增加0.80±0.16骨齡，治療過程中沒有任何不良反應發生。僅一名兒童治療後體內産生低效價抗生長激素抗體，但並未影響該名兒童之生長速度。

並列摘要

Five prepubertal children with previously untreated growth hormone deficiency were enrolled in this trial and treated with authentic recombinant human growth hormone hGH, 0.1 IU/Kg/day, subcutaneously, for one year. All of the children markedly increased their growth rate; the height velocity increased from 3.4±0.7 cm/yr to 11.3±2.0 cm/yr during one year's treatment. The height-standard deviation score for chronological age increased from -4.03±0.52 to -2.70±0.68. The bone age increased from 5.6±1.5 year before treatment to 6.4±1.6 years after one-year treatment. Only one child acquired low titer anti-hGH antibodies during the course of treatment (1:2 to 1:6). No untoward symptoms were complained of by these children and no biochemical abnormalities occurred except transient subclinical hypothyroidism in one child during the treatment course.

並列關鍵字

height velocity ； height-standard deviation score ； anti-GH antibody